🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
15.65
-0.28 (-1.76%)
At close: Nov 20, 2026, 4:00 PM EST
15.65
0.00 (0.00%)
After-hours: Nov 20, 2026, 7:00 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Q3 organic growth was 8%, with a 27% adjusted EBITDA margin as high-value capacity ramped. A temporary GLP-1 customer headwind resets 2027 growth expectations to low single digits, while margin expansion and higher free cash flow remain targets.

Dave Windley
Managing Director, Jefferies

Hi, everybody. I'm Dave Windley with Jefferies Healthcare Equity Research in the States. I cover the pharma services and packaging supply chain players, kind of the old gray hair in Jefferies Research, by the way. Last on the plank or furthest out on the plank. Pleased to have Stevanato Group here with us and the company's CEO, Franco Stevanato, to talk to us a little bit to lead off, and then we'll go into Q&A, and Giacomo Guiducci from IR here beside me. So, Franco, I'll hand it to you to lead off, please. Thank you.

Franco Stevanato
CEO, Stevanato Group

Thank you, David, and thank you to Jefferies to host Stevanato Group into this important conference. I have assembled some slides in order to summarize Stevanato Group, what is our core mission, what is our past, and our future expectation. Stevanato Group is a company that is present in the pharmaceutical space since more than 75 years. It is specialized in the production of glass container in the EZ-fill configuration for the pharmaceutical industry. In the last year, also we have enlarged our product portfolio in order to serve to our pharma customer also drug delivery system. Inside of Stevanato Group, we also we have one division, so-called engineering division, that is specialized first to bring the internal competitive advantage to Stevanato Group because it's the division who develop the technology in-house. Also, we sell inspection machine, assembly machine to the pharmaceutical company.

Practically, we build a value proposition in order to serve the best our pharmaceutical customer, our biologic customer, that they have a very strong pipeline in everything that is going to injection or self-medications. Today, also we are market leader worldwide on cartridges ready to fill. We are the second established player on syringes, and also we are the market leader on vial ready to fill. In order to see the result in Q3, sorry. In Q3, we were able to deliver a group level +8% with organic growth. The BDS segment was able to be in double digit. The BDS segment is in double digits since more than two years, but was offset by the decline on the revenue of the engineering division compared to two last year.

The major driver of the growth is thanks to our biologic market that is growing more and more, and we see more and more traction in what is related to our high-value product. Also, we are starting to see that our facility, our greenfield plants in Fishers and Latina, they're starting to go in full potential. This help us also to increase our marginality. In fact, we were able to deliver an adjusted EBITDA margin of 27% in the Q3. What is behind Stevanato Group? Let's start from the strong market environment. Also, we want to start to share the temporary headwind that we will face in 2027. Stevanato Group is serving practically the pharmaceutical industry. We have a strong market penetration into the top international customers. Also, we have a very big penetration in all the other regional customer worldwide.

We work with the top 25 global customer, and we have in our portfolio several hundred customers. More and more, we are focusing our strategy in what we call our high-value product solution. In particular, our EZ-fill platform, our syringes, cartridges, vial, and also we are extending our portfolio in drug delivery system, because biologic market is continue to grow. Years ago, we had the chance to be engaged by our two historical partner for insulin into the new opportunity, so-called GLP-1. In fact, we start with more than five, six, seven years ago to be validated on Nexa syringes, and we start to serve our two originator in syringes from our plants. Practically, in 2027, we will face a temporary headwind based on the fact that one of our big client on GLP-1, it will face a temporary headwind in 2027.

This is the reason why we are going to review a little bit. We have decided also to inform last week during our earning call that our guidance for the 2027 related to our growth, it will be not in high single- digit or low double- digit. We want to set a safe floor in the low single- digit growth. Independently from this, our goal is to continue to reinforce our marginality because we have a strong mix on high-value product, and we are continue to reinforce our operation in Fishers and Latina. The goal also to have a very big jump and boost in our generation of free cash flow. What is the situation? The macro environment of the market of biologic is grow. We are interacting with our customer. There are more than 9,000 molecule in phase II and phase III.

Through our tech center in Italy and in Boston, we are working on the early stage with our customers in order to fill the pipeline for the next year. GLP-1 is even more attractive tailwind. It's a phenomenal therapeutic drug class. It's only less than 10% of the full penetration of the population worldwide. The target of our customer is to be penetrated approximately 1.5 billion patient in the next years. Today, in United States, we are less than 10%. Outside of United States, we are approximately at 2%, 3%. Our goal is really to be engaged and to be partner from the day one. In fact, we are equally engaged with the two originators, and we have more than 30 customers on GLP-1 today, where we have opened more than 50 programs on cartridges ready to fill, on syringes Nexa, and also on devices. Why?

Because our goal is to replicate our strategy that we have done also in other therapeutic classes, like anesthetic, like insulin, like oncology, like heparin, to serve the originator, but also to well spread our validation to all the other biosimilar. 2027, there will be a temporary headwind because one of the two originator is facing some temporary headwind on demand, and we were not able to backfill all the demand. Was already the good news that we have many other incremental opportunity in other fields. Let's go to the conclusion. Stevanato Group, like I mentioned, is a 75 years old company. We have decided to went public in 2021 to raise money in order to heavily invest in capacity for high-value product in order to build a supply chain to be more in proximity to our customers in Europe, United States.

We develop a full product portfolio of high-value product. Our revenue today around the high-value product are approximately 46%, and our trajectory is to continue to growth. Our greenfield plants are up and running. More and more Fishers is delivery syringes to our American customers. We are starting to produce vial ready to fill. We are starting to add, starting to ramp up the big department production for auto-injector for one of our big clients in United States. And next year, we will also add capacity for Alba. Our European plants, they are moving on track. We are starting now to activate and to do the validation of one high-speed technology for cartridges ready to fill with a particular patent crimping station in our plants in Latina in order to serve this growing demand for biologic.

All our trajectory is online to continue to growth inside high single digit to low double digit, and to reinforce our marginality and to generate the appropriate cash in order really to do further investment in the future. Thank you.

Dave Windley
Managing Director, Jefferies

Great. Yeah. Franco, join us over here at the table. When we chatted in the middle of the year, the view, and albeit this may have been more of a general view, but the view was that the GLP-1 franchise was a durable double-digit growth opportunity, and your engineering business was making steady progress. That obviously changed pretty materially from that point to your third quarter earnings call. Maybe walk us through what specifically changed, what you learned, and when you learned it?

Franco Stevanato
CEO, Stevanato Group

Correct. I need to go back a little bit, couple of years. When we have the chance, we are honored to be engaged by our two originator in this new opportunity for GLP-1, our customer, they first validate in an equal way on syringes Nexa. Sorry.

Dave Windley
Managing Director, Jefferies

Yeah.

Franco Stevanato
CEO, Stevanato Group

On syringes Nexa, and also the second step for cartridges ready to fill, also one of these originator has engaged us also in the drug delivery system. Two years ago, they launched the product in the market. It was one originator was a little bit ahead to the other, and the other they follow. After two years, what's happened? The situation is this, that one originator have a very strong success, in particular in United States, they build a very strong market share position. The other have less success. This automatically have impact what? That in October of this year, when you review the new forecast for 2027, one have delivered a little bit high forecast, the other have done a very strong decline for the forecast 2027 for what is related to the syringes order in for this program.

We think this is a temporary headwind because these are customer that we serve both since more than 30 years. Historically, they had a very strong leadership position, and this is something that we think that we can It will be only temporary in 2027, David. In the meantime, what we are doing? We immediately started to backfill this capacity on Nexa syringes to three main area. First, we go to some other biologic customer on syringes like 2.25 ml, 3 ml, 1.5 ml, 5 ml, in order really to start to backfill with some biologic syringes where the marginality is more accretive. Second, the other originator have more strong demand because it's taking more traction in market share, and we receive some upside in term of order thanks to the fact that now the plants in Fishers is more up and running, have a very strong capacity.

Third, we have decided to temporarily backfill these syringes, this capacity in particular in Latina, with some non-high-value product syringes, in particular with some heparin customers that temporarily we have decided to keep it. So all overall, we have started to done a very good job in order to backfill this temporary drop. On top of this, for what is related to 2027, we have incremental revenue because we have add capacity for our Alba technology in Piombino Dese. We will have incremental revenue thanks to our cartridges ready to fill in Latina. We will have incremental revenue because in Germany, we are starting the new clean room for our Alina pen devices. In United States, we are ramping up more capacity for vial ready to fill, and we are launching this huge department for auto-injector for one big client.

All overall, we will able to backfill this temporary drop and to land with a low single-digit growth in 2027. If I can add a couple of word around again GLP-1, for sure, we have certain level of headache last week. I think we injected tons of pills of momentum for the headache that this customer give to us when they announced the forecast in October. It's also true that the outlook of our GLP-1 customers, both originator and the other program, are very intense. Today, in the medium term, we see many other programs that are going really to spread the risk that this therapeutic class is only in the head of two player in order to replicate the same that we see on anesthetic, on heparin, on other therapeutic classes.

On the top of this, we see that the biologic market is well spread through monoclonal antibody, through rare disease, oncology product, biosimilar, mRNA technology. There are many other therapeutic classes that in the medium long term, they will even more backfill and enhance Stevanato to be back on track on high single- digit, low double- digit growth.

Dave Windley
Managing Director, Jefferies

That is very helpful. Thank you. So, in your backfilling activity, as we discussed after the quarter, and as I understand it, had you not gotten this unfortunate news from your client, you would have expected to be on your low double-digit type trajectory of growth?

Franco Stevanato
CEO, Stevanato Group

Yeah. In particular, the BDS segment, because we have the combination of the demand of Nexa syringes, also this new incremental opportunity in biologic, correct? Our goal was to be on track with the result that we have done the last two years, that our average growth was more than 12% in the BDS segment, David.

Dave Windley
Managing Director, Jefferies

Great. The news perhaps took out maybe around 10% of that growth, 9%-10% of that growth, took you down to flat. You have backfilled back up to a few percentage points, something in the low single digits approach, or excuse me, growth. How much of that, what is the right word, voided capacity could you still resell?

Franco Stevanato
CEO, Stevanato Group

Today, on Nexa syringes, we have backfilled, but we still have free capacity in 2027 because we are starting to work with the existing customer where we already have the validation. Because of the massive capacity that this customer have free up temporarily, we were not able to backfill. So, we have still capacity, but it's taking time because if you already the stability and the validation done, it's a matter of how to ramp up, where to ramp up. For example, we have decided to keep in full potential the plant from Fishers because they have a strong demand, in particular with the other originator. We have played this backfill through the plants of Piombino Dese and Latina. Why? Because we have a higher number of validation, it was more easy to backfill.

But reality in 2027, we have additional free capacity on Nexa syringes because of sophistication of this program, you cannot replace the customer in three to six months. Our goal is to use all the 2027 to complete this backfill. Just for your information, David, when we received this bad news in October, it was very clear. We sit with all the management team and say: Guys, let's go out in 2027, what is a safe real number that we can show? Let's see how it's going to be the 2028, but removing the temporary headwind also in 2028 in order to be sure to be able to deliver high single- digit to low double- digit in 2028 also if this temporary headwind will not be back in order to go with a realistic safe number.

Dave Windley
Managing Director, Jefferies

I believe you said around the context of the call that the impact was not a result of, say, switch to oral or a switch from single dose to multi-dose format or a particular expected launch.

Franco Stevanato
CEO, Stevanato Group

No. It's only linked to the fact that they have a lot of syringes in stock, and they have a lower demand compared to the expectation, and they need time to mitigate the stock. On the top of this, with these originators, we are continuously the big program for cartridges ready to fill. If you stay on more a macro level, today we see our two originator growing rapidly on Nexa syringes, where there is not auto-injector, and they are heavily investing capacity for cartridges where there is the fixed dose pen. Also, the other 30 customers in GLP-1, the reason why we have more than 50 program, because the biosimilar, they have the tendency to mirror the same product portfolio of the originator. So, auto-injector, pen, and oral pills. But we don't see cannibalization between one to another product.

Dave Windley
Managing Director, Jefferies

Okay. Are those 30 customers, 50 programs, I assume you already had those slotted into your capacity. Are they part of the backfill? Can they be part of the backfill??

Franco Stevanato
CEO, Stevanato Group

The 30 customer, not really in 2027. There will be some, let's say, moving from phase III to early commercial product. The real backfill on Nexa syringes is doing by biologic customers for other treatment. The other originator on Nexa syringes and some heparin. This GLP-1 customer biosimilar, we expect more revenue 2028 and beyond, David.

Dave Windley
Managing Director, Jefferies

Yeah. I am going to pivot a little bit, still kind of talking about the same situation. I believe that you also identified that part of the headwind to your consolidated revenue growth for 2027 includes some rescheduling of programs or delay of programs in engineering.

Franco Stevanato
CEO, Stevanato Group

Correct.

Dave Windley
Managing Director, Jefferies

Talk about how that is related.

Franco Stevanato
CEO, Stevanato Group

This big client also, they have a little bit rescheduled their CapEx investment to us. We do not have yet information, but they most probably they will rephase in 2027. Correct. This is why Q3 was not at the level of our expectation from engineering point of view.

Dave Windley
Managing Director, Jefferies

Okay. So that is Q3, but that also is rescheduled out of 2027? I mean, there is a revenue impact in 2027, or no?

Franco Stevanato
CEO, Stevanato Group

No.

Dave Windley
Managing Director, Jefferies

No, that is not part of 2027.

Franco Stevanato
CEO, Stevanato Group

No, because in the budget expectation of engineering in 2027, we are building the budget for 2027 looking the pipeline order intake of all other customer not related to this one.

Dave Windley
Managing Director, Jefferies

Okay. I misunderstood that. How should we think then as you think about the mix? Your high-value product sales to GLP-1s, you have talked about high-run customer orders. High value is priced better, but high-run high value can be a little bit on the lower end.

Franco Stevanato
CEO, Stevanato Group

Correct.

Dave Windley
Managing Director, Jefferies

You are perhaps losing a little bit of that. You are replacing it with a combination of biologics.

Franco Stevanato
CEO, Stevanato Group

Correct.

Dave Windley
Managing Director, Jefferies

And standard product. What do you expect the blended margin impact of all of this to be?

Franco Stevanato
CEO, Stevanato Group

This high runner was inside of the category of high-value product, but in the lower range, more in the 40s of gross margin. We have backfilled with biologic clients where you are more sophisticated syringes, like 2.25 ml, 5 ml, 1.5 ml, where the quantity is smaller. We are in the range of 10 million, 20 million, 30 million pieces, but the price is much accretive. Also, the other originator is a high-value product, so this is compensated maybe a little bit better. Then the other are heparin market on a high-value product. All combined, the mix anyhow is much better than to run only this high runner. This is the final goal. We have a better mix in accretive margin.

Marco Dal Lago
CFO, Stevanato Group

So, if I may complement—

Franco Stevanato
CEO, Stevanato Group

Please.

Marco Dal Lago
CFO, Stevanato Group

—on that. For the portion of the volumes that we are confident we backfilled for 2027, margin-wise speaking, profitability speaking, this is not inferior, accretive. However, you need to consider that we still have a portion of capacity that is not backfilled, so overall, the impact still should be positive. However, we will provide detailed guidance in March.

Franco Stevanato
CEO, Stevanato Group

Sure.

Marco Dal Lago
CFO, Stevanato Group

What we have said also in last quarter earning call, I mean, few weeks back in the last earnings call, that on top of the low single-digit top-line growth, we do expect still to expand margins and have a step-up in free cash flow generation in fiscal 2027. The extent of it will be disclosed in the next earning call.

Franco Stevanato
CEO, Stevanato Group

You have also to consider, David, that we have incremental revenue on Alba. We have just installed the high-speed line for Alba technology in Piombino Dese. This is in the upper part of the range of gross margin. We are starting to ramp up the high-speed line for cartridges ready to fill. This is a high-value product. We are starting to ramp up Alina pen in Germany, and we bring even more in full potential the plants in Fishers. These are all elements that help really to generate a group level more positive gross margin.

Dave Windley
Managing Director, Jefferies

Okay. Is there any element of, as I think about the revenue mix across both segments, it sounds like the revenue headwind that you are absorbing from this client is all in BDS and all in high value. Is that correct?

Franco Stevanato
CEO, Stevanato Group

On 2026, we have seen some postponement of also some machine, also the engineering.

Dave Windley
Managing Director, Jefferies

Okay.

Franco Stevanato
CEO, Stevanato Group

In 2026, yes.

Dave Windley
Managing Director, Jefferies

That is affecting 2027?

Franco Stevanato
CEO, Stevanato Group

We don't know yet.

Dave Windley
Managing Director, Jefferies

Okay.

Franco Stevanato
CEO, Stevanato Group

But anyhow, the budget that we are building on for 2027, that is counting the low single- digit, is not considering from prudent point of view this postponement of this client for engineering.

Dave Windley
Managing Director, Jefferies

Okay. I guess what I'm getting at is, if it's a low single-digit growth rate overall, will BDS and engineering grow at about the same rate, or will BDS be more affected and engineering actually grow faster?

Franco Stevanato
CEO, Stevanato Group

Now, if I'm going to answer, I will be immediately killed by the board and my CFO.

Dave Windley
Managing Director, Jefferies

Uh-oh.

Franco Stevanato
CEO, Stevanato Group

Fortunately, my CFO is small, so I can take this risk to answer. So more or less, yes.

Dave Windley
Managing Director, Jefferies

Grow the same.

Franco Stevanato
CEO, Stevanato Group

Is represented, yes, the same.

Dave Windley
Managing Director, Jefferies

Grow the same. Okay, so no particular mix shift there.

Franco Stevanato
CEO, Stevanato Group

Subject to March, to confirm in March.

Dave Windley
Managing Director, Jefferies

I mean, I am obviously drilling deep on GLP-1s. You have mentioned other programs, biologics. We have generally talked about the pipeline there across multiple companies, the pipeline there being quite robust. You mentioned your go-to Nexa syringes, ready-to-fill cartridges, Alina pen.

Franco Stevanato
CEO, Stevanato Group

Vial ready to fill also.

Dave Windley
Managing Director, Jefferies

Vial, ready-to-fill vials. How is that pipeline building, I guess? Is that continuing, and to the extent that you also have any Annex 1 conversion upgrade benefits?

Franco Stevanato
CEO, Stevanato Group

On the pipeline, today, our tech center, our technical team is working hard to try to, in a scientific way, approach all these 9,000 molecules in phase II, phase III, and try to be validated at the early stage in order really to start the journey together with the customer at the beginning. This is bringing very strong positive results. Our next one today, where we see benefit is more traction on cartridges ready to fill and vial ready to fill, David, because clients, they prefer to go with the configuration of no glass-to-glass contact, in particular for cartridges. This is where we see an incremental number of program on cartridges ready to fill, also beyond the traditional clients.

Dave Windley
Managing Director, Jefferies

On Annex 1, are cartridges ready to fill?

Franco Stevanato
CEO, Stevanato Group

Annex 1 is helping to push more adoption of EZ-fill cartridges and EZ-fill vial.

Dave Windley
Managing Director, Jefferies

Okay. I think we're at time. I'll call it a time there. Thanks to the audience for your attention and for your attendance at our conference, and thank you to the Stevanato team for being here. Thank you.